Stoke Therapeutics appoints Eric Olson Chief Business Officer.

Stoke Therapeutics announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Olson will be responsible for leading and executing the Company’s global corporate strategy and business development. “We see a significant opportunity to expand the potential of Stoke’s first-in-class, disease-modifying approach to the treatment of many genetic diseases by upregulating protein expression with RNA based medicines,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “Eric’s deep experience leading global business development and corporate strategy teams, and in particular his most recent experience working for the foremost leader in RNA medicine, will make him instrumental in driving Stoke’s next phase of growth. With Eric and other recent executive hires, we are building a world-class leadership team with the expertise and commitment to Stoke’s mission of delivering new medicines to people living with severe diseases.”